07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Engineered Skin Substitute: Compassionate use program data

A compassionate use program in 16 pediatric patients with life-threatening, full-thickness, severe burns covering >50% total body surface area showed that PermaDerm prepared from split-thickness skin biopsies led to a mortality rate of 6.25% vs....
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET)

Ophthalmic disease INDICATION: Ophthalmic disease Mouse and fruit fly studies suggest MANF enhances the effectiveness of cell-based therapies for UV-damaged retinal tissue. In innate immune cells from Drosophila and mice, levels of MANF were higher...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Amarantus BioScience, Avant Diagnostics deal

Avant acquired Amarantus BioScience’s Amarantus Diagnostics Inc. subsidiary for 80 million shares of Avant stock valued at $25.6 million based on Avant’s close of $0.32 on May 11, the day before the deal closed. Amarantus...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Financial News

Amarantus BioScience completes private placement of senior convertible notes

Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif.   Business: Neurology, Cardiovascular   Date completed: 2016-04-21   Type: Private placement of senior convertible notes   Raised: $1.5 million   Shares outstanding prior: 29.6 million  ...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Financial News

Amarantus BioScience completes private placement of convertible preferred stock and warrants

Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif.   Business: Neurology, Cardiovascular   Date completed: 2016-01-27   Type: Private placement of convertible preferred stock and warrants   Raised: $1 million   Shares: 1,167   Shares...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Eltoprazine: Clinical trial data

A double-blind trial in 25 evaluable elderly AD patients with dementia who are aggressive showed that oral eltoprazine reduced SDAS total score to 16.9 points at day 29 from 25.1 points at baseline in severely...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Eltoprazine: Phase IIb halted

Amarantus halted enrollment in a double-blind, placebo-controlled, 4-way crossover, international Phase IIb trial of oral eltoprazine in about 60 patients due to an “internal prioritization.” The company expects to restart enrollment next year. Amarantus has...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Amarantus BioScience completes private placement of convertible preferred stock and warrants

Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif.   Business: Neurology, Cardiovascular   Date completed: 2015-10-01   Type: Private placement of convertible preferred stock and warrants   Raised: $2.8 million   Shares: 3,056   Price:...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Amarantus BioScience completes private placement of senior convertible notes

Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif.   Business: Neurology, Cardiovascular   Date completed: 2015-10-01   Type: Private placement of senior convertible notes   Raised: $2.8 million   Shares outstanding prior: 7.8 million  ...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

MSPrecise CSF Assay: Clinical trial data

An analysis of CSF cell pellets from 13 patients with confirmed RRMS and 26 patients with other neurological diseases (OND) showed that the MSPrecise CSF Assay had 75% sensitivity in the RRMS cohort and 88%...